Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Noridian Molecular Diagnostic (MolDX) Updates from Provider Suggestion Sep 17, 2024
Multi-Jurisdictional CAC Meeting Announcement - Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) - October 17, 2024, 2 - 4 p.m. CT Sep 13, 2024
Multijurisdictional Contractor Advisory Committee (CAC) Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) - Agenda Sep 13, 2024
Multijurisdictional Contractor Advisory Committee (CAC) Superficial Radiation Therapy (SRT) For The Treatment Of Nonmelanoma Skin Cancers (NMSC) - Key Questions Sep 13, 2024
Billing and Coding: MolDX: Blood Product Molecular Antigen Typing (A57124) - R5 - Effective October 1, 2024 Sep 12, 2024
Billing and Coding: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57421) - R11 - Effective October 1, 2024 Sep 12, 2024
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58679) - R7 - Effective October 1, 2024 Sep 12, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58996) - R6 - Effective October 1, 2024 Sep 12, 2024
Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R8 - Effective October 1, 2024 Sep 12, 2024
Self-Administered Drug Exclusion List (A53032) - R38 - Effective June 4, 2015 Sep 12, 2024
Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® Update (A54386) - R11 - Effective October 1, 2024 Sep 05, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R13 - Effective September 5, 2024 Sep 05, 2024
Intervertebral Disc Repair - Published for Review and Comments Aug 29, 2024
Open Meeting Announcement Intervertebral Disc Repair - October 7, 2024 Aug 29, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720)- R20 - Effective October 1, 2024 Aug 29, 2024
Open Meeting Announcement - Multiple MolDX Policies MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis and MolDX: Genetic Testing for Heritable Thoracic Aortic Disease - October 10, 2024 Aug 29, 2024
Multiple MolDX Policies- MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis and MolDX: Genetic Testing for Heritable Thoracic Aortic Disease - Published for Review and Comments Aug 29, 2024
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39467) - R1 - Effective August 22, 2024 Aug 22, 2024
MolDX: Molecular Testing for Solid Organ Allograft Rejection Aug 16, 2024
Noridian Molecular Diagnostic Service New Look Aug 09, 2024
Local Coverage Determinations (LCDs) Finalized - Effective September 22, 2024 Aug 08, 2024
Billing and Coding: MolDX: Afirma™ Assay by Veracyte (A54356) Retirement - Effective July 28, 2024 Aug 01, 2024
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58679) - R6 - Effective August 1, 2024 Aug 01, 2024
Billing and Coding MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R19 - Effective August 1, 2024 Aug 01, 2024
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms - Published for Review and Comments Aug 01, 2024
Open Meeting Announcement - MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms - September 13, 2024 Aug 01, 2024
Facet Joint Interventions for Pain Management L38801 - R3 and Billing and Coding: Facet Joint Interventions for Pain Management A58403 - R5 - Effective July 7, 2024 Aug 01, 2024
MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38339) - R2 - Effective July 25, 2024 Jul 25, 2024
Self-Administered Drug Exclusion List (A53032) - R37 - Effective July 1, 2024 Jul 18, 2024
Polysomnography and Other Sleep Studies - Published for Review and Comments Jul 18, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R18 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57331) - R12 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R7 - Effective July 11, 2024 Jul 11, 2024
Billing and Coding: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (A59521) - R2 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R17 - Effective July 1, 2024 Jul 05, 2024
Self-Administered Drug Exclusion List (A53032) - R36 - Effective July 1, 2024 Jul 05, 2024
Local Coverage Determinations (LCDs) Finalized - Effective August 18, 2024 Jul 05, 2024
Billing and Coding: MolDX: Proteomics Testing (A59641) - R5 - Effective July 1, 2024 Jul 05, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R19 - Effective July 1, 2024 Jul 05, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Jun 27, 2024
MolDX: Pigmented Lesion Assay (L38151) - R1 - Effective June 20, 2024 Jun 20, 2024
MolDX: Melanoma Risk Stratification Molecular Testing (L37750) - R6 - Effective June 20, 2024 Jun 20, 2024
Local Coverage Determinations (LCDs) Finalized - Effective July 28, 2024 Jun 13, 2024
Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF) (A56572) - R6 - Effective January 10, 2021 Jun 13, 2024
Billing and Coding: Epidural Steroid Injections for Pain Management (A58993) - R3 -November 15, 2023 Jun 11, 2024
Billing and Coding: Sacroiliac Joint Injections and Procedures (A59244) - R5 - Effective June 1, 2024 Jun 11, 2024
Billing and Coding: Leadless Pacemakers (A59819) - Effective June 6, 2024 Jun 07, 2024
Billing and Coding: MolDX: Billing and Coding: MolDx: ResponseDX Tissue of Origin (A54494) Retirement - Effective May 30, 2024 Jun 06, 2024
Billing and Coding: MolDX: PAX6 Gene Sequencing (A55625) Retirement - Effective May 29, 2024 Jun 06, 2024
Billing and Coding: MolDX: MMACHC Test (A55288) Retirement - Effective May 30, 2024 Jun 06, 2024